Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Synaptic dysfunction in Alzheimer’s disease

Thomas Südhof, MD, Stanford University School of Medicine, Standford, CA, discusses the link between synaptic dysfunction and typical neuropathological features in Alzheimer’s disease. Although it is well known that in Alzheimer’s disease, the best correlation between the cognitive decline exists with synapse loss, whether synapse function is impaired before the actual loss of synapses is unknown. Synaptic dysfunction could cause significant changes that lead to Alzheimer’s disease or could be a consequence of the pathological process. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.


Prof. Südhof serves on the board of directors for Sanofi SA and for CytoDel Inc., and is a consultant for Alector, Boost, Recognify, Simcere, REATA, Catalio, Danaher, Elysium, Jupiter, and NeuraLight. Most of these companies have drug programs directly or distantly related to Alzheimer’s or Parkinson’s disease.